Pfizer Inc
NYSE: PFE
$25.72
+$0.12 (+0.5%)
Closing Price on March 14, 2025
PFE Articles
Despite the never-ending election cycle, there actually is a clear path for the Dow to hit 30,000 as soon as early 2020, if only a few things come to fruition. There does not even have to be a big...
Published:
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
As of the most recently reported settlement date, short sellers still favored Microsoft, Intel and Pfizer above all other Dow stocks.
Published:
With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the Dow are still holding the index back from even stronger gains.
Published:
Shares of Merck and Pfizer both got boosts after they reported their most recent quarterly results before the opening bell Tuesday.
Published:
Merck and Pfizer are set to report their most recent quarterly results before the opening bell tomorrow. Pfizer is one of the most shorted of all Dow stocks.
Published:
Six of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Published:
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
As of the most recently reported period, short sellers still favored Microsoft, Intel and Pfizer above all other Dow stocks.
Published:
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Published:
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
Published:
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
As of the most recently reported period, short sellers favored Microsoft, Intel and Pfizer above all other Dow stocks.
Published:
The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid long-term prospects.
Published:
Pfizer has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.